Key result
High cumulative atherogenic-frailty index exposure is linked to ~4-fold higher risk of cardiometabolic multimorbidity.
Why the study?
Effective tools for early risk stratification of cardiometabolic multimorbidity remain limited, and the combined impact of atherogenic dyslipidaemia and frailty on CMM development is poorly understood.
Does higher cumulative exposure and longitudinal trajectory of the combined atherogenic-frailty index (AIP-FI) increase the risk of incident cardiometabolic multimorbidity in adults aged ≥45 years?
Cohort (n=4,157)
Yes
Does higher cumulative exposure and longitudinal trajectory of the combined atherogenic-frailty index (AIP-FI) increase the risk of incident cardiometabolic multimorbidity in adults aged ≥45 years?
Hazard Ratio: 3.95 (95% CI 2.95–5.29)
The combined atherogenic-frailty index (AIP-FI) serves as a composite biomarker whose cumulative burden and longitudinal trajectory can significantly improve early risk stratification for cardiometabolic multimorbidity in middle-aged and older adults.
Background: Cardiometabolic multimorbidity (CMM) poses a growing global health burden, yet effective tools for early risk stratification remain limited. The combined impact of atherogenic dyslipidaemia and physiological frailty, captured by the atherogenic index of plasma-frailty index (AIP-FI), on CMM development is poorly understood. This study aimed to investigate the associations of cumulative exposure and longitudinal trajectories of AIP-FI with incident CMM. Methods: This prospective cohort study included 4,157 participants aged ≥45 years without baseline CMM from CHARLS. The AIP-FI was constructed as the product of AIP and a 37-deficit frailty index. Cumulative AIP-FI was calculated from repeated measurements. Longitudinal trajectories were identified using K-means clustering. Associations with incident CMM were evaluated by multivariable Cox models, RCS, K-M curves, ROC/NRI/IDI, mediation, interaction, subgroup, and sensitivity analyses. Results: Over a mean 8.5-year follow-up, 612 incident CMM cases occurred. Both higher baseline and cumulative AIP-FI were significantly associated with increased CMM risk, with cumulative exposure showing a stronger effect (fully-adjusted HR per SD increment: 1.46; 95% CI = 1.38-1.54). Participants in the highest quartile of cumulative AIP-FI had a near 4-fold higher CMM risk compared to the lowest (HR = 3.95; 95% CI = 2.95-5.29). Clustering analyses revealed that groups with high-stable AIP-FI exhibited the highest CMM risks. Cumulative AIP-FI demonstrated superior predictive performance for CMM (AUC = 71.17%) and significantly improved risk reclassification over traditional markers (NRI = 0.157). Mediation analyses suggested bidirectional synergistic effects between AIP and FI. Conclusions: In this national cohort, both the cumulative burden and adverse longitudinal trajectories of AIP-FI were independently associated with an elevated risk of CMM. Dynamic monitoring of this composite biomarker could facilitate the early identification of high-risk individuals, thereby informing targeted prevention strategies for middle-aged and older adults in China.
No takes yet. Share an insight, caveat, or question.
巫海娣 et al. (2026) conducted a cohort in Cardiometabolic multimorbidity (n=4,157). Cumulative atherogenic index of plasma-frailty index (AIP-FI) vs. Lowest quartile of cumulative AIP-FI was evaluated on Incident cardiometabolic multimorbidity (CMM) (HR 3.95, 95% CI 2.95-5.29). Being in the highest quartile of cumulative atherogenic-frailty index exposure was associated with a near 4-fold higher risk of incident cardiometabolic multimorbidity (HR 3.95; 95% CI 2.95-5.29).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: